Contrary to traditional anti-inflammatory therapies such as corticosteroids and non-specific immunosuppressants that bear the risk of cancer recurrence, the anti-CTLA4 treatment seems to have a dual beneficial effect for cancer patients. The gene discussed is CTLA4; the disease is cancer.